Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer

E A Kim; E S Gershtein; I V Vysotskaya; N E Kushlinskii

doi:10.1007/s10517-008-0061-2

Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer

Bull Exp Biol Med. 2008 Feb;145(2):245-8. doi: 10.1007/s10517-008-0061-2.

Authors

E A Kim¹, E S Gershtein, I V Vysotskaya, N E Kushlinskii

Affiliation

¹ N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow. helene-kim@yandex.ru

PMID: 19023980
DOI: 10.1007/s10517-008-0061-2

Abstract

We revealed a significant positive correlation between the concentrations of tissue VEGF and its receptor VEGFR2 in the primary tumor. The degree and direction of changes in the content of VEGF and VEGFR2 in cytosols of tumors from patients with locally spread breast cancer during the preoperation therapy depended on initial levels of these parameters. We found that the expression of the studied factors depended on the degree of therapeutic pathomorphosis in the tumor tissue.

MeSH terms

Adult
Aged
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism*
Breast Neoplasms / pathology
Female
Humans
Middle Aged
Neoadjuvant Therapy*
Vascular Endothelial Growth Factor A / genetics
Vascular Endothelial Growth Factor A / metabolism*
Vascular Endothelial Growth Factor Receptor-2 / genetics
Vascular Endothelial Growth Factor Receptor-2 / metabolism*
Young Adult

Substances

Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2